| 2017 | 2018 | 2019 | 2020 (projected) | Current Assets | 249.6 K | 11.03 M | 12.68 M | 4.14 M | Total Assets | 249.6 K | 12.53 M | 14.41 M | 7.82 M |
Is Neu Base price going to go ballistic in July?
 | By Rifka Kats | Macroaxis Story |
Why analysts lower the company buy or sell consensus to Buy? Neu Base Average Equity is expected to increase significantly based on the last few years of reporting. The past year's Average Equity was at 10.65 Million. The current year Enterprise Value is expected to grow to about 106.6 M, whereas Earnings before Tax are expected to decline to (24.9 M). Today's article will digest Neu Base as a potential position in July. What exactly are Neu Base shareholders getting in July? Analysts have now less confidence in the stock as compared to a month ago. The current buy or sell recommendation of 6 analysts is Buy. The entity slowly supersedes the market. We have analyzed thirty-four available fundamentals for Neu Base, which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Neu Base Therapeutics financials, including its net income, short ratio, working capital, as well as the relationship between the debt to equity and beta . Given that Neu Base Therapeutics has a price to earning of (4.17) X, we recommend you to check Neu Base last-minute market performance to make sure the company can sustain itself down the road. Use Neu Base to enhance returns of your portfolios. The stock experiences a very speculative upward sentiment. Check odds of Neu Base to be traded at $12.9 in 30 days.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
On a scale of 0 to 100, Neu Base holds a performance score of 11. The company secures a Beta (Market Risk) of 0.2149, which conveys that not very significant volatility relative to the market. Let's try to break down what Neu Base's beta means in this case. As returns on the market increase, Neu Base returns are expected to increase less than the market. However, during the bear market, the loss on holding Neu Base will be expected to be smaller as well. Although it is vital to follow to Neu Base Therapeutics price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Neu Base, which you can use to evaluate the performance of the firm. Please exercises Neu Base Therapeutics skewness, and the relationship between the potential upside and rate of daily change to make a quick decision on whether Neu Base Therapeutics current price movements will revert. The company currently holds 122.92 K in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Neu Base Therapeutics has a current ratio of 4.32, suggesting that it is liquid enough and is able to pay its financial obligations when they are due. The firm's average rating is Buy from 6 analysts. Our buy, hold, or sell recommendation tool can be used to cross verify current analyst consensus on Neu Base Therapeutics and to analyze the entity potential to grow in the current economic cycle. What is the right price you would pay to acquire a share of NeuBase Therapeutics? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.
Watch out for price decline
Please consider monitoring NeuBase Therapeutics on a daily basis if you are holding a position in it. NeuBase Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as NeuBase Therapeutics stock to be traded above the $1 level to remain listed. If NeuBase Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
What is happening with NeuBase Therapeutics this year
Annual and quarterly reports issued by NeuBase Therapeutics are formal financial statements that are published yearly and quarterly and sent to NeuBase stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as NeuBase Therapeutics often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
NeuBase Therapeutics Gross Profit
NeuBase Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing NeuBase Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show NeuBase Therapeutics Gross Profit growth over the last 10 years. Please check NeuBase Therapeutics' gross profit and other fundamental indicators for more details.
Another Deeper Perspective
Average experts consensus on Neu Base has changed. Analysts have now less confidence in the organization as compared to a month ago. The current buy or sell recommendation of 6 analysts is Buy. Neu Base currently holds 122.92 K in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. This firm has a current ratio of 4.32, suggesting that it is liquid enough and is able to pay its financial obligations when they are due. Neu Base reported previous year revenue of 4.71 M. Net Loss for the year was (26.96 M) with profit before overhead, payroll, taxes, and interest of 3.65 M. Neu Base preserves 2.54 m of working capital. Neu Base Average Equity is increasing over the last 8 years. The previous year's value of Neu Base Average Equity was 12,711,267. Neu Base Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years.
null
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of NeuBase Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.